Get the Stockscreener App
1.69
12.44%
-0.24
After Hours:
1.67
-0.02
-1.18%
Akebia Therapeutics Inc stock is traded at $1.69, with a volume of 9.60M.
It is down -12.44% in the last 24 hours and down -21.03% over the past month.
Akebia Therapeutics Inc is a fully integrated biopharmaceutical company. The Company's operating segment is the business of developing and commercializing novel therapeutics for people with kidney disease. The current portfolio of the company includes Auryxia (ferric citrate), a medicine approved and marketed in the United States for the control of serum phosphorus levels in adult patients with dialysis-dependent chronic kidney disease and the treatment of iron deficiency anemia, in adult patients with non-dialysis-dependent chronic kidney disease, Vafseo (vadadustat), an oral hypoxia-inducible factor prolyl hydroxylase, inhibitor, is approved in Japan for the treatment of anemia due to chronic kidney disease, in adult patients, HIF-PH inhibitors in preclinical development.
See More
Previous Close:
$1.93
Open:
$1.8
24h Volume:
9.60M
Relative Volume:
4.21
Market Cap:
$368.73M
Revenue:
$194.75M
Net Income/Loss:
$-51.26M
P/E Ratio:
-6.0357
EPS:
-0.28
Net Cash Flow:
$-23.38M
1W Performance:
-11.98%
1M Performance:
-21.03%
6M Performance:
+15.75%
1Y Performance:
+19.86%
1-Day Range:
$1.525
$1.84
1-Week Range:
$1.525
$1.99
52-Week Range:
$0.80
$2.48
Akebia Therapeutics Inc Stock (AKBA) Company Profile
Name
Akebia Therapeutics Inc
Sector
Phone
617-871-2098
Address
245 FIRST STREET, CAMBRIDGE, MA
Compare AKBA with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
AKBA
Akebia Therapeutics Inc
|
1.69 | 368.73M | 194.75M | -51.26M | -23.38M | -0.28 |
|
ZTS
Zoetis Inc
|
160.06 | 71.67B | 9.26B | 2.49B | 2.30B | 5.47 |
|
TAK
Takeda Pharmaceutical Co Adr
|
15.03 | 47.44B | 30.25B | 1.37B | 5.08B | 0.4257 |
|
HLN
Haleon Plc Adr
|
10.19 | 46.08B | 14.35B | 1.85B | 0 | 0.4023 |
|
TEVA
Teva Pharmaceutical Industries Ltd Adr
|
16.46 | 18.86B | 16.54B | -1.64B | 749.00M | -1.45 |
|
ITCI
Intra Cellular Therapies Inc
|
131.36 | 13.97B | 612.78M | -86.37M | -62.91M | -0.87 |
Akebia Therapeutics Inc Stock (AKBA) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Nov-29-23 | Resumed | BTIG Research | Buy |
| Aug-28-23 | Upgrade | H.C. Wainwright | Neutral → Buy |
| May-31-23 | Upgrade | Piper Sandler | Neutral → Overweight |
| Mar-31-22 | Downgrade | H.C. Wainwright | Buy → Neutral |
| Mar-31-22 | Downgrade | Mizuho | Buy → Neutral |
| Mar-31-22 | Downgrade | Needham | Buy → Hold |
| Mar-31-22 | Downgrade | Piper Sandler | Overweight → Neutral |
| Mar-08-21 | Initiated | Cantor Fitzgerald | Overweight |
| Jan-29-21 | Downgrade | JP Morgan | Neutral → Underweight |
| Nov-14-19 | Reiterated | Needham | Buy |
| Aug-06-19 | Reiterated | H.C. Wainwright | Buy |
| Jul-11-19 | Reiterated | H.C. Wainwright | Buy |
| May-02-19 | Initiated | JP Morgan | Overweight |
| Mar-20-19 | Initiated | Citigroup | Neutral |
| Sep-07-18 | Resumed | Morgan Stanley | Equal-Weight |
| Aug-10-18 | Reiterated | Needham | Buy |
| Jun-06-18 | Reiterated | H.C. Wainwright | Buy |
| Dec-19-17 | Initiated | Piper Jaffray | Overweight |
| Dec-07-17 | Initiated | BTIG Research | Buy |
| Sep-15-17 | Initiated | RBC Capital Mkts | Sector Perform |
| Jul-10-17 | Reiterated | H.C. Wainwright | Buy |
| Apr-27-17 | Reiterated | H.C. Wainwright | Buy |
| Apr-27-17 | Reiterated | Needham | Buy |
| Dec-27-16 | Reiterated | H.C. Wainwright | Buy |
| Dec-20-16 | Reiterated | JMP Securities | Mkt Outperform |
| Nov-15-16 | Initiated | Aegis Capital | Buy |
| Sep-29-16 | Initiated | Brean Capital | Buy |
| Mar-16-16 | Reiterated | Needham | Buy |
| Jan-21-16 | Initiated | Credit Suisse | Neutral |
View All
Akebia Therapeutics Inc Stock (AKBA) Latest News
Akebia Therapeutics Reports Progress in Vafseo Launch - TipRanks
Akebia Therapeutics: Q4 Earnings Snapshot - mySA
Sector Update: Health Care Stocks Slipping Late Afternoon -March 13, 2025 at 04:07 pm EDT - Marketscreener.com
Akebia Therapeutics Shares Fall After Q4 Results -March 13, 2025 at 02:52 pm EDT - Marketscreener.com
Akebia stock slumps after Q4 earnings miss (AKBA:NASDAQ) - Seeking Alpha
Akebia slumps after Q4 earnings miss - MSN
Akebia Therapeutics, Inc. Reports Earnings Results for the Fourth Quarter and Full Year Ended December 31, 2024 - Marketscreener.com
Earnings call transcript: Akebia Therapeutics Q4 2024 misses EPS forecasts By Investing.com - Investing.com UK
Akebia Therapeutics (AKBA) Reports Q4 Loss, Tops Revenue Estimates - Yahoo Finance
Akebia Therapeutics, Inc. SEC 10-K Report - TradingView
AKEBIA THERAPEUTICS Earnings Results: $AKBA Reports Quarterly Earnings - Nasdaq
Akebia Therapeutics Reports Fourth Quarter and Full Year - GlobeNewswire
Akebia Therapeutics Reports Fourth Quarter and Full Year 2024 Financial Results and Vafseo® (vadadustat) Commercial Launch Progress Update - Yahoo Finance
Akebia Therapeutics Reports Inducement Grants Under Nasdaq Listi - GuruFocus.com
Thinking about buying stock in VinFast Auto, Akebia Therapeutics - GuruFocus.com
AKEBIA THERAPEUTICS Earnings Preview: Recent $AKBA Insider Trading, Hedge Fund Activity, and More - Nasdaq
Exploring High Growth Tech Stocks In The US Market - Simply Wall St
Akebia Therapeutics, Inc. (NASDAQ:AKBA) Stock Holdings Increased by Rhumbline Advisers - Defense World
Akebia Therapeutics, Inc. to Host Earnings Call - ACCESS Newswire
Akebia Therapeutics, Inc. Scheduled to Report Q4 and Full Year 2024 Financial Results on March 13, 2025 - Nasdaq
Akebia Therapeutics to Report Fourth Quarter and Full Year 2024 Financial Results and Discuss Recent Business Highlights - The Manila Times
Akebia Therapeutics to Report Fourth Quarter and Full Year - GlobeNewswire
When Will Akebia Report Q4 Earnings? Key Date for Biotech Investors - StockTitan
Akebia Therapeutics (NASDAQ:AKBA) Stock Rating Lowered by StockNews.com - Defense World
Akebia Therapeutics (AKBA) to Release Earnings on Thursday - Defense World
Akebia Therapeutics Executives Sell Shares to Cover Tax Obligations - TradingView
Akebia Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) - GlobeNewswire
Akebia Issues 13,525 Stock Options: What This Means for Shareholder Dilution - StockTitan
Akebia Therapeutics (NASDAQ:AKBA) Stock Rating Upgraded by StockNews.com - MarketBeat
Akebia Therapeutics (NASDAQ:AKBA investor five-year losses grow to 80% as the stock sheds US$55m this past week - Simply Wall St
Akebia Therapeutics (NASDAQ:AKBA) Cut to Sell at StockNews.com - Defense World
Short Interest in Akebia Therapeutics, Inc. (NASDAQ:AKBA) Declines By 19.7% - MarketBeat
Akebia Therapeutics (NASDAQ:AKBA) Upgraded to Hold at StockNews.com - MarketBeat
Akebia Therapeutics (NASDAQ:AKBA) Rating Increased to Hold at StockNews.com - Defense World
Akebia Therapeutics extends loan agreement, receives $9.3M - MSN
Akebia Therapeutics: Still Bullish On Vafseo As Auryxia's Revenues Decline - Seeking Alpha
Akebia Therapeutics, Inc. (NASDAQ:AKBA) CEO John P. Butler Sells 144,250 Shares - MarketBeat
Akebia Therapeutics, Inc. (NASDAQ:AKBA) Insider Sells $116,804.10 in Stock - MarketBeat
Akebia Therapeutics, Inc. (NASDAQ:AKBA) SVP Sells $106,062.60 in Stock - MarketBeat
Insider Selling: Akebia Therapeutics, Inc. (NASDAQ:AKBA) CAO Sells 30,202 Shares of Stock - MarketBeat
Akebia Therapeutics extends loan agreement, receives $9.3M By Investing.com - Investing.com Canada
$10.7 Billion Healthcare Mobile Robots Market Outlook, 2030 - GlobeNewswire
$10.7 Billion Healthcare Mobile Robots Market Outlook, 2030 by Type, End Use and RegionAkebia Therapeutics, ABB, Aethon, Omron Corp., and Amazon Lead the Competition - Yahoo Finance
Akebia Therapeutics' chief accounting officer sells $63,424 in stock - MSN
Akebia Therapeutics' chief commercial officer sells $116,804 in stock - MSN
Akebia therapeutics' chief medical officer sells $106,062 in stock By Investing.com - Investing.com South Africa
Akebia therapeutics' chief medical officer sells $106,062 in stock - MSN
Akebia Therapeutics CEO John Butler sells $302,925 in stock By Investing.com - Investing.com Canada
Akebia Therapeutics' chief commercial officer sells $116,804 in stock By Investing.com - Investing.com South Africa
Akebia Therapeutics Inc Stock (AKBA) Financials Data
Revenue
Net Income
Cash Flow
EPS
0.77%
0.63%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):